CELL MOL IMMUNOL 润色咨询

Cellular & Molecular Immunology

出版年份:2004 年文章数:575 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:6.9% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2024-01-27 ms8000000965566049 来自北京

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:无

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2023-05-21 侠胆医心 来自上海

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学
    经验分享:一、基本情况:
    CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。
    二、收录范围:
    CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:
    ·临床免疫学·比较免疫学·免疫生物学
    ·免疫遗传学·免疫学技术·免疫病理学
    ·免疫药理学·感染免疫学·神经免疫学
    ·移植免疫学·肿瘤免疫学·兽医免疫学
    三、发文量
    近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。
    四、影响因子
    CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。
    五、投稿费用:
    作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2022-04-28 146de754m00暂无昵称

    审稿速度:6.0 | 投稿命中率:5.0
    偏重的研究方向:免疫学
    经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂

    8

    展开8条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2023-06-24 侠胆医心 来自上海

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:免疫遗传;移植免疫;免疫调节
    经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。
    CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。
    医学1区,免疫学1区,预计在今年影响因子可能还会增长。

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2023-05-10 liu89liu89liu 来自山东省

    审稿速度:6.0 | 投稿命中率:5.0
    偏重的研究方向:免疫
    经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2021-01-14 ms4000001412745107

    under submission 是表示没投稿成功吗

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2020-12-17 YJ1203

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受

    3

    展开3条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2019-01-30 乌龟茶茶

    我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?977804261_32132706 2018-12-04 发表::
    投稿四天,请问Decision sent to author 是什么意思?
    977804261_32132706 2018-12-04 09:26:00 发表:
    投稿四天,请问Decision sent to author 是什么意思?

    977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2019-12-13 ∠※∠※

    貌似明年IF可能会降到8以下,7左右。

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1314, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2131390, encodeId=9b3b2131390ee, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:CMI杂志要求越来越高,非常难投,送审难度高于NC, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKa43ldfNGibG8bgibDMo4oOMahsicxpAHMnhxicqWPvfFt60oAukcCA11Pm6HAvaTuF8cPux8LpBicG6Q/132, createdBy=67662542542, createdName=liu89liu89liu, createdTime=Wed May 10 13:09:03 CST 2023, time=2023-05-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=916572, encodeId=97739165e20f, content=under submission 是表示没投稿成功吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211201/d84136dee0dd4d68848cc44db50f719c/6ffa0936d1994653900ac5b4c9c895b0.jpg, createdBy=5c5f5450836, createdName=ms4000001412745107, createdTime=Thu Jan 14 16:42:46 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908990, encodeId=7b19908990b2, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:杂志很高效,投稿后大概半个月给了意见,补实验两个月左右,修回后两天接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f102059491, createdName=YJ1203, createdTime=Thu Dec 17 23:31:45 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566333, encodeId=014856633327, content=我的现在也是这个,不知道什么意思,您现在知道什么意思了吗?可否告知?<span class="quote">977804261_32132706 2018-12-04 发表::<br>投稿四天,请问Decision sent to author 是什么意思?</span><span class="quote">977804261_32132706 2018-12-04 09:26:00 发表:<br>投稿四天,请问Decision sent to author 是什么意思?</span>, beContent=977804261_32132706 2018-12-04 发表:: 投稿四天,请问Decision sent to author 是什么意思?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/03de00270512f76c71ee0be6e395142e.jpg, createdBy=2d582540931, createdName=乌龟茶茶, createdTime=Wed Jan 30 00:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581419, encodeId=8da25814197d, content=貌似明年IF可能会降到8以下,7左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73ea1969766, createdName=∠※∠※, createdTime=Fri Dec 13 00:00:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564000, encodeId=3ef85640009a, content=投稿四天,请问Decision sent to author 是什么意思?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f542076906, createdName=977804261_32132706, createdTime=Tue Dec 04 09:26:00 CST 2018, time=2018-12-04, status=1, ipAttribution=)]
    2018-12-04 977804261_32132706

    投稿四天,请问Decision sent to author 是什么意思?

    0

共50条页码: 1/5页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分